Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
p53 suppresses lipid droplet–fueled tumorigenesis through phosphatidylcholine
Xiuduan Xu, … , Peng Li, Peng Jiang
Xiuduan Xu, … , Peng Li, Peng Jiang
Published January 9, 2024
Citation Information: J Clin Invest. 2024;134(4):e171788. https://doi.org/10.1172/JCI171788.
View: Text | PDF
Research Article Cell biology

p53 suppresses lipid droplet–fueled tumorigenesis through phosphatidylcholine

  • Text
  • PDF
Abstract

Choline deficiency causes disorders including hepatic abnormalities and is associated with an increased risk of multiple types of cancer. Here, by choline-free diet–associated RNA-Seq analyses, we found that the tumor suppressor p53 drives the Kennedy pathway via PCYT1B to control the growth of lipid droplets (LDs) and their fueling role in tumorigenesis. Mechanistically, through upregulation of PCYT1B, p53 channeled depleted choline stores to phosphatidylcholine (PC) biosynthesis during choline starvation, thus preventing LD coalescence. Cells lacking p53 failed to complete this response to choline depletion, leading to hepatic steatosis and tumorigenesis, and these effects could be reversed by enforcement of PCYT1B expression or restoration of PC abundance. Furthermore, loss of p53 or defects in the Kennedy pathway increased surface localization of hormone-sensitive lipase on LDs to release specific fatty acids that fueled tumor cells in vivo and in vitro. Thus, p53 loss leads to dysregulation of choline metabolism and LD growth and couples perturbed LD homeostasis to tumorigenesis.

Authors

Xiuduan Xu, Jianqin Wang, Li Xu, Peng Li, Peng Jiang

×

Figure 2

p53 drives the Kennedy pathway and transcriptionally upregulates PCYT1B expression.

Options: View larger image (or click on image) Download as PowerPoint
p53 drives the Kennedy pathway and transcriptionally upregulates PCYT1B ...
(A) Atom-transition map showing the isotope carbon-13 (13C) transfers from [1,2-13C2]choline through the PC synthetic pathway. Open circles represent carbon-12 (12C); blue circles indicate 13C from [1,2-13C2]choline. (B and C) Normalized peak areas of m+2 13C-labeled metabolites from p53+/+ and p53–/– HepG2 cells cultured with choline-free medium and pulse-labeled with [1,2-13C2]choline. (B) 13C-labeled choline, phosphocholine, and citicoline. (C) 13C-labeled PC. The isotopic labeling of each metabolite is denoted as m + n, where n is the number of 13C atoms. n = 3 samples per treatment. (D and F) Mice were fed a choline-deficient or normal diet for 4 weeks (n = 3 mice per group). Liver tissues were analyzed by quantitative reverse transcriptase PCR (RT-PCR) (D) and Western blot (F). (E and G) HepG2 cells cultured in choline-free medium or complete medium were analyzed by quantitative RT-PCR (E) and Western blot (G). (H) Immunohistochemistry of mouse liver tissues. Scale bar: 100 μm. (I) HepG2 cells were cultured with [1,2-13C2]choline for 30 minutes, and relative PCYT1 activity was determined. (J) Liver tissue from p53+/+ mice fed a normal or choline-free diet was lysed and immunoprecipitated with anti-p53 or IgG antibody. The bound DNA was amplified by quantitative RT-PCR. (K) Luciferase constructs containing WT or mutant response elements (REs) were transfected into HEK93T cells together with FLAG-p53 or vector control. Renilla vector pRL-CMV was used as a transfection internal control. Relative luciferase activity was calculated by division of FLAG-p53 samples over the FLAG vector control samples. Data are mean ± SD. Each experiment was carried out at least 3 times. P values were calculated by 2-tailed unpaired Student’s t test (B, C, and I–K) or 2-way ANOVA with Tukey’s multiple-comparison test (D and E). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts